Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy
Nat Commun
.
2021 Aug 10;12(1):4833.
doi: 10.1038/s41467-021-24837-8.
Authors
Mathieu Roumiguie
1
2
,
Alberto Contreras-Sanz
3
,
Gunjan Kumar
3
,
Peter C Black
3
Affiliations
1
Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. roumiguie_mathieu@yahoo.fr.
2
Department of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, Toulouse, France. roumiguie_mathieu@yahoo.fr.
3
Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
PMID:
34376681
PMCID:
PMC8355281
DOI:
10.1038/s41467-021-24837-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Chemotherapy, Adjuvant
Cisplatin*
Neoadjuvant Therapy*
Substances
Cisplatin